[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
|
Health See other Health Articles Title: Cancer cure at bottom of the ocean Stock Gumshoe ids company experimenting with the natural source drug. The spiel comes from Michael Robinson, and he’s selling his Radical Technology Profits newsletter ($1,950/year) by promising access to a special “ET-73 Prospectus” that will let you buy round lots of shares in a special company that has a miraculous cancer cure. Sound familiar? Yes, he promised something quite similar earlier this summer, and his colleague Keith Fitz-Gerald had a very similar ad back in February that implied he could give you special “round lot” access to a pre-IPO company before it makes its (presumably explosive) debut on the Nasdaq. So what is it? Well, let me give you just a taste of the spiel first: “… when this University of Illinois biochemist strapped a scuba tank to his back and plunged into the warm Caribbean water, he was just trying to enjoy his vacation. “But when he caught a glimpse of a small orange mass near the ocean floor, his natural scientific curiosity took over. “He emerged from the water that day with a small bag of what would soon be known as Ecteinascidin. (Based on its active molecules registry number I’ll just abbreviate it to ET-73.) “ET-73 is one of the rarest materials on the planet. “Today, it’s worth $58.9 million per ounce…. “… a Harvard report has revealed that ET-73 is… ‘Hundreds to thousands of times more powerful than any cancer treatment now in use.’ “And it destroys rare and aggressive cancer cells like nothing that’s come before it.” And this is, apparently, a drug that’s already being made and sold: “In Europe, ET-73 has already been granted approval under the ‘exceptional circumstance’ clause for use when ‘other cancer medicines have stopped working.’ “However, this is just the beginning. “As the results of study after study come in, the hope is that ET-73 will be an effective treatment – not just for people who are suffering from advanced stages of Soft Tissue Sarcoma – people who are faced with no other choice but to turn to last resort drugs… “The hope is that this medical miracle could soon be used to safely treat those who suffer from numerous forms of cancer, in all stages. “Last year, sales of ET-73 reached $110 million – so not even enough to fill two thimbles. “But the story moving forward is completely different. “In late 2015, ET-73 was approved by the Japanese Ministry of Health. “Shortly after that, the FDA approved it for use in the United States. “And today, doctors at Dana Farber, MD Anderson, the Mayo Clinic, Massachusetts General, and leading cancer facilities around the world have rushed to implement this treatment in their groundbreaking studies.” “Worldwide Sales of Drugs Derived From ET-73 Are Projected to Aggressively Rise as High as $1.9 Billion By 2020. “And One Tiny Company Has a Monopoly on It.” So who is it? As it was last time, this is the Spanish biotech PharmaMar (PHM in Madrid, PHMMF OTC in the US) PharmaMar has two drugs right now that are either commercially available or nearly so, Yondelis for soft tissue sarcoma and Breast Cancer (second and third line treatment, with European approvals leading US approvals so far) and Aplidin for fourth line multiple myeloma, along with PM1183, which is in clinical trials for a variety of cancers (including one in Phase III trials). And yes, the “round lots” do trade at about $245 — the stock is currently at $2.79 in US over the counter (OTC) trading, and it closed at 2.49 euros in Madrid trading (that’s the home exchange). Post Comment Private Reply Ignore Thread
|
||
|
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|
||